PURPOSE: The aim of this study was the health-economic analysis of MR imaging in the diagnostics of @entity263 (PCa) before execution of a first biopsy. MATERIALS AND METHODS: The health-economic analysis included four steps: modeling, determination of probabilities, evaluation, and sensitivity analyses. We performed an effectiveness analysis from the @entity1 perspective as well as a cost-effectiveness and a cost-utility analysis from the health insurance perspective for Austria and Germany. The effectiveness and cost-effectiveness analysis used a hypothetical cohort of 100,000 @entity1 . The result parameters were number of biopsies, number of detected PCa, and monetary costs. For the cost-efficiency analysis, the result parameters, quality-adjusted life years (QALYs) and costs, were calculated for an individual @entity1 . RESULTS: The efficiency analysis showed that MRI before a first biopsy can prevent ca. 64,000 unnecessary biopsies/ 100,000 @entity1 . The diagnostic efficiency was higher by a factor of 1.7. Due to MRI, eight PCas were additionally detected. From a health insurance perspective, MRI was not cost-effective. Extra costs of ca. 42 m.     per 100,000 @entity1 and of 650     per prevented biopsy were calculated. The costs per detected PCa were increased by 1395    . The attainable QALYs were a little higher for the MRI alternative, which was therefore not dominated. CONCLUSION: Our results do not permit a clear recommendation for or against the application of MRI in the diagnostics of PCa. From the @entity1 perspective, it is to be endorsed due to the higher medical efficiency. However, it is connected with higher health insurance costs.

[Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['suspicious prostate carcinoma']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
